ABSTRACT Liver-directed gene therapy will be applica- 
occlusion. In this study, we employed this method and concentrated retroviral preparations to achieve trasduction of up to 15% ofhepatocytes as determined by a quantitative PCR assay.
As an initial step toward identifying promoters which lead to high-level long-term expression of retroviral transduced genes, we used our in vivo delivery system to compare the Moloney murine leukemia virus long terminal repeat (LTR) promoter with the promoter for the large subunit of murine RNA polymerase II (Pol-fi). Human al-antitrypsin (hAAT) was used as the reporter gene to facilitate long-term analysis of expression. Serum hAAT levels were higher for the Pol-II promoter (143 ng/ml) than for the LTR promoter (50 ng/ml). This difference was consistent with the higher transduction frequency observed for the Pol-H-hAAT vector. Although serum hAAT expression was sained for up to 1 year in six of eight Pol-fl-hAAT-transduced rats and three of five LTR-hAATtransduced rats and was proportional to hAAT mRNA level and proviral DNA frequency, in vivo expression was signiicantly lower than in transduced tissue culture cells. We conclude that a high frequency of in vivo transduction can be achieved by using retroviral vectors and our rapid transduction protocol, but transduced gene expression remais a serious problem. The quantitative assays described herein will facilitate in vivo comparisons of gene regulatory elements.
Liver-directed gene therapy could revolutionize the treatment of many inherited hematologic and metabolic diseases (1) (2) (3) . Although both ex vivo (4, 5) and in vivo (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) approaches have been used to transfer genes into mammalian hepatocytes, widespread application in humans awaits a simplified delivery system and identification of elements that maximize expression.
The ex vivo approach requires hepatocyte harvest, in vitro transduction with retrovirus, and reimplantation via the portal circulation. Chowdhury et al. (4) used this technique to ameliorate hypercholesterolemia for up to 6 months in Watanabe rabbits by transducing hepatocytes with a low density lipoprotein receptor gene. Using a similar ex vivo protocol, Kay et al. (5) delivered a human al-antitrypsin (hAAT) gene to canine hepatocytes. Although serum hAAT at concentrations up to 1000 ng/ml was observed at 7 days after transduction, expression declined shortly thereafter, presumably due to inactivation of the cytomegalovirus (CMV) promoter. The ex vivo technique's major liabilities include the potential for contamination during large-scale hepatocyte culture (=108 hepatocytes per kg of recipient body mass) and the relatively low proportion (-2%) of the hepatocyte mass that can be safely reintroduced.
In vivo delivery of foreign genes to hepatocytes has been accomplished by using: (i) intravenous injection of plasmid DNA complexed with liposomes (12) or asialoglycoproteins (13) ; (ii) intraportal (14, 16) packaging cells (19) and colonies were selected with 250 nM methotrexate (Mtx; Sigma) (20) . Transduced GP+E-86 cells were cocultured for 8 days with GP+envAM12 fibroblasts (21) with Polybrene (Sigma) at 8 tug/ml. Amphotropic colonies were selected wi'h hygromycin B at 100 tig/ml (22) and 250 nM Mtx and screened by infecting NIH 3T3 cells and measuring hAAT production 72 hr later. Mtx-resistance (MtxR) titers were determined on NIH 3T3 cells (18) , and high-titer clones were proven free of replication-competent helper virus (18) .
In Vivo Hepatocyte Transduction. Ten to 15 ml of medium was collected from confluent 15-cm plates of amphotropic packaging cells, centrifuged at 500 x g, passed through a 0.45-,um-pore cellulose acetate filter, spiked with Polybrene (40 jg/ml, final concentration), and stored on ice until use.
To obtain concentrated retrovirus, the conditioned medium was ultracentrifuged at 15,000 rpm in a Beckman SW28 rotor for 90 min, after which the pellets were resuspended in fresh medium, refiltered, and treated as above. Adult male SpragueDawley rats (Sasco, Omaha, NE), weighing 200-275 g, received standard institutional animal care. Twenty-four hours after 70% hepatectomy, in vivo hepatocyte transduction was performed as described (11) .
Total Liver RNA and DNA Isolations. One gram of liver was homogenized in 10 ml of 4 M guanidinium thiocyanate (Fluka)/25 mM sodium citrate/0.5% Sarkosyl/0.1 M 2-mercaptoethanol. RNA was isolated from half of the sample by the acid pH phenol/chloroform extraction method (23) . DNA was isolated from the other portion in a room devoid of retrovirus and plasmid DNA by neutral pH phenol/ chloroform/isoamyl alcohol (PCA) extraction, proteinase K digestion, and RNase A digestion (ref. 24 , pp. E3-E4, 7.71-7.78, and 9.16-9.21, respectively). DNA was chromatographed on a Sephadex G-25 column (Pharmacia), and the early fractions containing high molecular weight DNA were quantitated by fluorometry (25) .
RNase Protection Assay. Antisense RNA probes with specific activity of 6 x 108 cpm/,ug of RNA and 100,g of total RNA per sample were used in an RNase protection assay as p. 10.14). After quantitation, the membrane was stripped and rehybridized with an LFABP probe.
RESULTS
Production of Retroviral Vectors. Previous studies demonstrated our ability to deliver retrovirus to regenerating hepatocytes by the hepatic in-flow occlusion/portal vein injection method (11) . To facilitate quantitation of long-term expression, we constructed two retroviral vectors carrying the cDNA for a serum protein, hAAT (Fig. 1) . In LTR-hAAT, expression of hAAT was driven by the Mo-MLV LTR. In Pol-II-hAAT, transcription could proceed from either the LTR or the internally located Pol-II promoter. The IRES (30) allowed translation of the mutant murine dihydrofolate reductase gene to occur in a cap-independent fashion and ensured that it could be translated equally well from either a full-length or an internally initiated transcript. Amphotropic producer clones had MtxR titers of 1 x 106 colony-forming units (cfu)/ml (for Pol-II-hAAT) and 2 x 105 cfu/ml (for Effect of Retrovirus Concentration on in Vivo Hepatocyte Transduction. We reasoned that in vivo transduction frequency might be improved by increasing the number of retroviral particles injected. Our ultracentrifugation protocol resulted in a 24-fold concentration by volume, and a 10-fold increase in MtxR titers (cfu/ml). When delivered in vivo, concentrated retrovirus yielded a 7-fold (Pol-II-hAAT) or 31-fold (LTR-hAAT) increase in serum hAAT as compared with an unconcentrated batch of the same viral preparation (Fig. 2) , demonstrating that in vivo transduction frequencies are proportional to the number of retroviral particles delivered. Although the cellular Pol-II promoter appeared to yield higher serum hAAT expression (143 ± 47 ng/ml; mean + SEM) than the viral LTR promoter (50 ± 25 ng/ml), the difference was not statistically significant [P > 0.10; Student's t test for unpaired data (two-tailed) (31) ]. These levels represent 1/7000 (Pol-II) and 1/20,000 (LTR) of the serum hAAT level in normal humans (-1 mg/ml) (32) . Portal vein injection of concentrated Pol-II retrovirus into rats at the time of partial hepatectomy, or into rats which did not receive a hepatectomy, resulted in no detectable hAAT at 1 week after injection (data not shown), demonstrating that serum hAAT is dependent upon replication of hepatocytes at the time of injection. Control rats which received a f-galactosidase- ,ig/ml. In vivo hepatocyte transductions were performed with 5 ml of concentrated or unconcentrated virus. Serum hAAT was measured at 1 week after transduction and plotted (mean ± SEM) for rats receiving concentrated (C) or unconcentrated (U) Pol-II-hAAT or LTR-hAAT retrovirus. P values are for each C vs. U. Long-term survival was 85% for animals receiving concentrated or unconcentrated retrovirus.
containing retrovirus had no detectable serum hAAT (data not shown).
Long-Term hAAT Expression After in Vivo Transduction.
Rats which received concentrated retrovirus in the above experiment were followed long term for serum hAAT expression (Fig. 3) . Of the six surviving Pol-II-hAAT rats, two had hAAT decline to <3 ng/ml, while the other four maintained detectable levels; the average serum hAAT at 1 week was 122.6 ± 46.6 ng/ml, and at 1 year it was 37. The hAAT signal in 100 ,g of liver RNA from LTR-hAAT rats (Fig. 4B, lanes 16-19) or Pol-II-hAAT rats (C, lanes 4-14) was as high as that found in 0.01 or 0.05 ug, respectively, of human liver RNA, leading to an estimated hAAT RNA level of 1/10,000 or 1/2000, respectively, that of normal human liver. This leads us to conclude that low levels of hAAT mRNA are responsible for the low hAAT protein production.
The above RNase protection assay does not differentiate between LTR-and Pol-II-initiated transcripts. To define the Proc. Natl. Acad. Sci. USA 91 (1994) transcription initiation site, a second RNase protection assay was used in which the probe spanned the Pol-I initiation site (Fig. 4D) . More than 90o of transcripts initiate from the LTR promoter in the packaging cell line (Fig. 4E, lane 3) , or in transduced cells (data not shown). In contrast, RNA derived from a Pol-II-hAAT-transduced rat liver showed similar levels of initiation from the Pol-II promoter and from the LTR. Thus Pol-II-initiated transcripts represent a much higher fraction of total transcripts in vivo as compared with in vitro.
PCR Quantitation of Proviral DNA in Transduced Rodents.
To quantitate transduction efficiency, we isolated genomic DNA from rat liver biopsy samples and used multiplex PCR to amplify proviral (IRES) and rat genomic (LFABP) DNA sequences, and amplification was followed by Southern blotting (Fig. 5) . As expected, nontransduced rat liver DNA had a signal after probing with LFABP but not IRES (lane 2). To create standards with known proportions of retroviral DNA, DNA was isolated from an LTR-hAAT-transduced NIH 3T3 clone which contained (by Southern blot) a single copy of proviral DNA per cell, and this was diluted with normal rat genomic DNA (lanes 2-9). For these standards, the ratio of IRES to LFABP signal increased linearly as the relative copy number of LTR-hAAT DNA increased. The rat genomic DNA signal (LFABP) was not saturated when 50 ng of DNA was added to the PCR mixture, as both the IRES and LFABP signals increased proportionately when the mass of NIH 3T3 cell DNA (containing 0.3% LTR-hAAT DNA) was increased from 25 to 100 ng (lanes 8 and 9). PCRs were also performed on liver DNA from transduced rats (Fig. 5, lanes 10-14) . The ratio of IRES to LFABP signal was compared with the standard curve to determine the integration frequency of proviral DNA. In contrast to the relatively low amounts of hAAT protein and mRNA, proviral DNA frequency varied from 5% to 15% for the Pol-II-hAAT rats. Transduction frequencies for the LTR-hAAT rats were somewhat lower at 0.2-1.0%. Table 1 summarizes the amounts of proviral DNA, hAAT mRNA, and serum hAAT observed in several transduced rodents. These results indicated that (i) high transduction frequencies could be attained with our method and (ii) the lower expression in the LTRhAAT rats as compared with the Pol-II-hAAT rats was due to less frequent proviral integration.
DISCUSSION
Hepatic gene therapy is increasingly attractive, given the recent success of both ex vivo (4, 5) and in vivo (6-17) transduction protocols. Its widespread application would be facilitated by a delivery system which avoids large-scale hepatocyte culture or a complicated asanguineous liver perfusion system. We have previously reported an in vivo hepatocyte transduction protocol which entails 70% hepatectomy followed 24 hr later by portal vein injection of a retroviral vector during hepatic in-flow occlusion (11) Fig. 5 ; Table 1 ). Although these transduction frequencies were determined by using PCR, we believe they are valid because (i) internal standards were used to normalize for PCR efficiency; (ii) Southern blots of genomic DNA from rats 12 and 13 (without PCR) confirmed a provirus DNA frequency of z10% (data not shown); and (iii) these frequencies are consistent with our results with a retrovirus of lower titer containing the f-galactosidase gene (11) . Our transduction efficiency is higher than that reported for intraparenchymal injection (0.6%) (7), portal vein injection without occlusion of incoming blood flow (1%) (10) , and the ex vivo approach (1%) (4, 5) , and it is similar to the efficiencies attained with a complicated asanguineous liver perfusion technique (1-5%) (8, 9) .
The second major goal of these studies was to develop methods of quantitating expression from different promoter elements in vivo. Although the Pol-II-hAAT retroviral vector yielded 3-to 5-fold higher serum hAAT and liver hAAT mRNA levels than LTR-hAAT, these differences reflect the higher transduction frequency observed for Pol-II-hAAT, which is consistent with its 5-fold higher in vitro titers. Although the level of expression was maintained in most animals for at least 1 (Fig. 4) .
tPercentage ofhepatocytes transduced with retrovirus as determined by four separate experiments performed in duplicate (Fig. 5) . tRatio of DNA to RNA (column 5 . column 6) . Percentage relative to human serum (Fig. 3) .
VFell to zero.
Several investigators have demonstrated that strong viral promoters including the CMV (5, 10, 33) and Mo-MLV LTR (34) can be inactivated in vivo in fibroblasts (33, 34) or hepatocytes (5, 10) . In contrast, the LTR promoter has directed expression of 3-galactosidase (8) and neomycin resistance (7) for up to 100 days in animal livers, although the significant increase in expression upon the addition of 5-azacytidine suggested that the LTR promoter was attenuated (but not inactivated) by DNA methylation in vivo (7) . Our results suggest that attenuation and/or inactivation of the LTR does indeed occur in vivo in rat hepatocytes. For all animals, expression of the LTR in hepatocytes in vivo is only r-1% of that observed in cultured tissue cells. In addition, we noted that two of five LTR-hAAT rats (Fig. 3A) lost expression within 3 months after transduction, although PCR analysis of liver DNA revealed proviral DNA frequencies of 0.1-0.3% (data not shown). We conclude that the LTR promoter is a poor choice for achieving high level in vivo expression in liver cells.
The use of constitutive cellular promoters might circumvent the viral promoter attenuation problem. For example, Scharfmann et al. (33) showed that the dihydrofolate reductase promoter was expressed long term in fibroblasts in vivo, while the CMV promoter was not. Similarly, Chowdhury et al. (4) observed persistent in vivo expression from the chicken f-actin promoter. The Pol-II-hAAT retrovirus used in our studies can initiate transcription from either the 5' LTR or the internal Pol-I1 promoter. Fig. 4E suggests that much of the overall decrease in expression in Pol-II-hAAT rats is due to attenuation from the LTR promoter and that expression from the internal Pol-II promoter (albeit weak) is relatively constant. This is consistent with the results ofSoriano et al. (35) , who found that an internal promoter was not influenced by inactivation of the upstream LTR promoter in embryonic stem cells.
Liver-specific promoters may further increase in vivo expression from a retroviral vector. Kay et al. (10) tested in vivo hAAT expression from a retroviral vector carrying a 2.8-kb liver-specific murine albumin promoter-enhancer. They demonstrated serum hAAT levels of =500 ng/ml, which suggests that the mouse albumin promoter/enhancer construct is 5-to 10-fold stronger than the Pol-IH and Mo-MLV LTR promoters, if indeed the provirus integration frequency is 1%. In contrast, the phosphoenolpyruvate carboxykinase promoter led to low levels of expression from a retroviral (6) or a plasmid (17) vector.
These results lead us to conclude that an hAAT gene can be efficiently delivered to hepatocytes in vivo and expressed long term. Although up to 15% of hepatocytes can be transduced, the highest level of expression obtained (=300 ng/ml) is only a fraction of that required for gene therapy of a,-antitrypsin deficiency. This suggests that increasing expression from a retroviral vector by identifying strong promoters should be a major focus ofgene therapy research. The use of our portal vein injection/hepatic in-flow occlusion method will allow rapid assessment of multiple promoters in vivo and might be applicable for gene therapy in humans once safety concerns are adequately addressed.
